ECNP-PsychX talks
Bringing you the latest science in psychiatry
About PsychX and ECNP
We believe in making mental health expertise readily available to all. This vision led to the creation of PsychX, a platform to champion both emerging and established voices in the mental health domain. Every month, we host short online discussions spanning various mental health topics, making knowledge accessible without registration fees or hidden costs.
Join these high-relevance free online sessions, featuring monthly explorations into both clinical and experimental facets of psychiatry.
In 2022, PsychX and ECNP started collaborating. As from 2023, all PsychX talks were transferred to ECNP.
How to join the talks
Click on the button below to join:
Join here
or via the direct meeting link.
Meeting ID: 854 0080 8569 Passcode: PSYCHX
Upcoming talks
Mark your calendars for our lineup! We convene every first Monday of the month.
2 December 2024, 16.30 CET
David Nutt, United Kingdom
Title, outline and bio to be announced.
5 March 2025, 16.30 CET
Real-world effectiveness of psychopharmacological treatments: recent insights
Jari Tiihonen, Sweden and Finland
Recent evidence has shown that in schizophrenia, only 10–20% of atypical patients are selected for RCTs investigating the efficacy of antipsychotic treatment. Therefore, the generalizability of RCTs to real-world patient population can be questioned. In addition, in RCTs, it is practically impossible to study the risk of death or rare severe side effects related to specific medication. This presentation will inform how large nation-wide registers can be used to study these issues.
Finland and Sweden have unique person identification number for each individual that enables linking of data on filled prescriptions in pharmacies, hospital admissions, work disability benefits, and mortality. This presentation will review methodological issues related to RCTs versus observational studies and show results on real-world effectiveness of specific psychotropic medications related to risk of relapse, work disability, and death among patients with non-affective psychosis, bipolar disorder, substance use disorder, and personality disorders.
Jari is professor at the department of clinical neuroscience in Karolinska Institutet, Stockholm, Sweden, and also professor and Chairman at the University of Eastern Finland, department of forensic psychiatry, Kuopio, Finland. The main topics in his scientific work in psychiatry are psychopharmacology, stem cell studies to elucidate neurobiology of schizophrenia, functional brain imaging, autoradiography studies on dopamine and serotonin receptors and transporters in the human brain, and epidemiology, genetics and neurobiology of schizophrenia, substance dependence, and violent and suicidal behavior. His H-index is 77.
Jari has developed pharmacoepidemiological methodology to study real-world effectiveness of psychopharmacological treatments by using nation-wide databases, and he has also conducted several randomized controlled trials on treatment-resistant schizophrenia and substance dependence.
PsychX Programme Committee
Visit this page to find out about the PsychX Programme Committee and its members, goals, composition and time commitment.
Previous talks
View here previous PsychX talks.
